ORIGINAL RESEARCH article

Front. Immunol.

Sec. Cancer Immunity and Immunotherapy

Volume 16 - 2025 | doi: 10.3389/fimmu.2025.1590951

This article is part of the Research TopicHarnessing Molecular Insights for Enhanced Drug Sensitivity and Immunotherapy in CancerView all 35 articles

Single-Cell Ligand-Receptor Profiling Reveals an Immunotherapy-Responsive Subtype and Prognostic Signature in Triple-Negative Breast Cancer

Provisionally accepted
Jiahui  QiJiahui Qi1Chuanzhi  ChenChuanzhi Chen2Weichao  LinWeichao Lin2Chunlan  FuChunlan Fu3Xin  JinXin Jin4*
  • 1Wenzhou Medical University, Wenzhou, Zhejiang Province, China
  • 2First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang Province, China
  • 3Zhuji Affiliated Hospital of Wenzhou Medical University, Zhuji, China
  • 4Zhejiang Zhuji People's Hospital, Zhuji, China

The final, formatted version of the article will be published soon.

Triple-negative breast cancer (TNBC) is an aggressive form of cancer that lacks specific targeted therapies. Although ligand-receptor (LR) interactions play a crucial role in intercellular communication and contribute to tumor heterogeneity, their molecular details and potential as prognostic or predictive markers in TNBC have not been thoroughly investigated.We analyzed single-cell RNA sequencing data to categorize TNBC into 12 subgroups and 10 distinct cell types. From this dataset, we identified LR pairs that exhibited significant intercellular crosstalk and evaluated their prognostic relevance in a METABRIC TNBC cohort (n = 298). Through consensus clustering of these LR pairs, two molecular subtypes were defined. Key LR genes were then selected using Lasso regression and stepwise multivariate analysis to build an LR-based prognostic scoring system (LR.score), which was validated using both the METABRIC and GSE58812 datasets (n = 107). Additionally, we performed siRNA-mediated knockdown of the CXCL9/CXCR3 axis in MDA-MB-231 cells, confirming the knockdown via RT-qPCR and Western blot. The functional impact was assessed through proliferation, colony formation, and wound healing assays.Results: One subtype (Clust1) demonstrated strong immune cell infiltration, higher immune scores, and enrichment in pathways such as epithelial-mesenchymal transition, angiogenesis, and KRAS signaling-indicative of a basal-like, immune-active phenotype. Among the LR pairs, the CXCL9-CXCR3 axis was identified as a key factor in immune cell recruitment and anti-tumor responses. Functionally, silencing the CXCL9/CXCR3 axis significantly diminished the proliferation, colony formation, and migratory capabilities of MDA-MB-231 cells. Moreover, a higher LR.score was correlated with poorer overall survival (HR = 1.69, 95% CI = 1.12-2.56, P < 0.05) and reduced response to immune checkpoint inhibitors (ICIs), while patients with lower LR.score showed increased sensitivity to ICIs, particularly in anti-PD-L1 cohorts.The LR.score serves as an independent prognostic factor and a reliable predictor of immunotherapy response in TNBC. Targeting crucial LR interactions, especially the CXCL9-CXCR3 axis, may enhance immunotherapeutic efficacy and refine prognostic evaluations, paving the way for improved treatment strategies in TNBC.

Keywords: Tumor Microenvironment, ligand-receptor interactions, Triple-negative breast cancer, Prognostic model, Immunotherapy, immune checkpoints

Received: 10 Mar 2025; Accepted: 01 May 2025.

Copyright: © 2025 Qi, Chen, Lin, Fu and Jin. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

* Correspondence: Xin Jin, Zhejiang Zhuji People's Hospital, Zhuji, China

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.